These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24612257)

  • 1. Rising cost of anticancer drugs in Australia.
    Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
    Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rising costs of drugs in hospitals in the period 1996-2000 and over the next few years].
    Breekveldt-Postma NS; Zwart-van Rijkom JE; Egberts AC; Leufkens HG; Herings RM
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2547-51. PubMed ID: 12532669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
    Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
    Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
    Savage P; Mahmoud S; Patel Y; Kantarjian H
    J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social Security cost-of-living adjustments and the Consumer Price Index.
    Burdick C; Fisher L
    Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.
    Bennette CS; Richards C; Sullivan SD; Ramsey SD
    Health Aff (Millwood); 2016 May; 35(5):805-12. PubMed ID: 27140986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Australian rise of esomeprazole-was expenditure on samples a contributor?
    Kyle GJ; Nissen LM; Tett SE
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):62-8. PubMed ID: 19111014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rising Cost of Anticancer Medications in the United States.
    Jackson K; Nahata MC
    Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.